Pfizer’s Massive Tax Dodge
The pharma giant previously received billions in federal funding and raked in huge profits, but owes nothing in 2023 income taxes thanks to legal loopholes and Trump-era tax cuts.
Health Care
Deep dives into the political corruption and corporate bureaucracy that keeps Americans sick while making executives rich.
Where Nursing Homes Hide Their Profits
While industry leaders plead poverty to fight a proposed staffing standard, private equity owners are funneling cash into their affiliated real estate and management firms.
The New War Over Generic Drugs
Why are generic drugmakers fighting a plan to let them make more medicines?
SIROTA’S SIGNALS: Cheeseburgers vs. Water
Plus, a single graph explains Boeing’s crisis, Apple tries to censor its regulator, and Wall Street data debunks the GOP’s anti-ESG crusade.
This New Lawsuit Could Rescind Your Health Care Benefits
Right-wing federal appeal judges signal they support repeal of the no-cost preventive care mandate, all but guaranteeing a Supreme Court showdown.
Pharma’s Dems Are Doing Trump’s Dirty Work On Drug Prices
As the first-ever Medicare drug-price negotiations take shape, Big Pharma-backed Democrats want to limit the number of costly medicines regulators can target.
Pharma’s Secret Middlemen Are Poisoning Health Care
Following a lobbying blitz, Congress might punt all efforts to stop shadowy pharmacy benefit managers from inflating drug prices and killing small pharmacies.
YOU LOVE TO SEE IT: States Depoliticize Utility Bills
Plus, Oregon aims to limit corporate takeover of medical clinics, federal regulators investigate private use of corporate aircrafts, and more student debt relief is on the way.
YOU LOVE TO SEE IT: Mega-Merger (Potentially) Blocked On Aisle Five
Plus, consumers could be protected from insurer meltdowns, dueling communities reach rare agreement over water rights, and rural America scores access to clean water.
Americans Paid $11 Billion To Make Drugs You Can’t Afford
A bombshell report reveals that taxpayers spent billions developing medicines that drugmakers say shouldn’t face Medicare price negotiations.